Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Executive Summary

Herceptin and Rituxan biosimilar applications expected to reach FDA early next year while EMA review is ongoing; timing could be another test for 351(k) pathway in US.

Advertisement

Related Content

Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Subcutaneous Rituximab Seems Headed For US FDA Advisory Panel OK
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Neupogen Off-Label Use Complicates Data Extrapolation For Sandoz’s Biosimilar

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel